[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital das Clínicas de Ribeirão Preto\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":134},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,84,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100650369","rosuvastatin-and-losartan-pharmacokinetics-after-bariatric-surgery-100650369",false,"NCT07748273","Rosuvastatin and Losartan Pharmacokinetics After Bariatric Surgery","Comparative Evaluation of Rosuvastatin and Losartan Pharmacokinetics and the Associations Between Gut Microbiota Alterations and Changes in Systemic Drug Exposure in Patients Undergoing Roux-en-Y Gastric Bypass or Sleeve Gastrectomy","BARI-PK","Inclusion Criteria:\n\n* Adults aged 18 to 65 years;\n* Formal clinical indication for RYGB or sleeve gastrectomy after multidisciplinary assessment;\n* Bariatric surgery scheduled and no previous bariatric procedure;\n* Able to understand the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Moderate or severe hepatic impairment, liver enzymes greater than 3 times the upper limit of normal, or Child-Pugh class B or C.\n* Estimated glomerular filtration rate below 30 mL\u002Fmin\u002F1.73 m².\n* Concomitant use of drugs that substantially affect rosuvastatin pharmacokinetics and cannot be temporarily discontinued, including cyclosporine, gemfibrozil, or potent OATP1B1\u002FBCRP or CYP2C9 inhibitors.\n* Systemic antibiotic use within 3 months or probiotic, prebiotic, or synbiotic use within 4 weeks before sampling.\n* Continuous current rosuvastatin or other statin therapy unless medically discontinued with an adequate washout period under physician supervision.\n* Clinically relevant baseline hypotension, significant hyperkalemia, renal impairment, or another condition that makes a losartan test dose unsafe.\n* Severe postoperative complication preventing oral dosing, including active gastrointestinal leak, intractable vomiting, or severe anastomotic stenosis.\n* Pregnancy. Participants of childbearing potential undergo routine preoperative beta-hCG testing.","ALL","18 Years","65 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This prospective, open-label, non-randomized pharmacokinetic study will evaluate how Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy affect systemic exposure to single oral test doses of rosuvastatin and losartan. Sixty adults scheduled for bariatric surgery will enter one of two parallel groups according to the clinically selected operation (30 RYGB and 30 sleeve gastrectomy). Each participant will receive rosuvastatin 10 mg and losartan 25 mg once within 30 days before surgery and again approximately 12 weeks after surgery. Plasma samples collected before dosing and at 1.5 and 4 hours after dosing will be used with maximum a posteriori Bayesian estimation to estimate individual pharmacokinetic parameters. In the 30-participant RYGB group only, paired stool samples will be used to explore gut microbiota and untargeted fecal metabolomic changes. The primary objective is to compare within-participant changes and between-procedure differences in drug exposure after bariatric surgery.",[28,29,30,31],"Obesity & Overweight","Bariatric Surgery","Pharmacokinetics After Oral Intake","Drug Absorption",[33,34,35,36,37,38,39,40],"Roux-en-Y gastric bypass","sleeve gastrectomy","rosuvastatin","losartan","E-3174","gut microbiota","metabolomics","systemic exposure","NOT_YET_RECRUITING","2026-08-03",{"date":44,"type":45},"2026-08-05","ACTUAL",{"date":47,"type":22},"2026-08-02",{"date":49,"type":22},"2027-05-15",{"name":51,"class":52},"Hospital das Clínicas de Ribeirão Preto","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":83,"locationsCount":53},"100648967","transit-bipartition-after-sleeve-gastrectomy-100648967","NCT07728682","Transit Bipartition After Sleeve Gastrectomy","Clinical, Metabolic, and Physiological Evaluation of Conversion From Sleeve Gastrectomy to Intestinal Transit Bipartition","BTT-SLEEVE","Inclusion Criteria:\n\n* Age 18 years or older;\n* Previous sleeve gastrectomy for the treatment of obesity;\n* Follow-up at the HCRP gastrosurgery\u002Fbariatric surgery outpatient clinic through 2026;\n* Clinical evaluation supporting revisional conversion to intestinal transit bipartition;\n* Willingness to undergo the new surgical procedure and provide written informed consent.\n\nExclusion Criteria:\n\n* Liver cirrhosis;\n* Absence of willingness to undergo a new surgical procedure.",{"count":63,"type":22},40,[25],"This prospective, single-center study will evaluate adults undergoing revisional conversion from sleeve gastrectomy to intestinal transit bipartition. Forty participants will complete clinical, endoscopic, physiological, metabolic, hormonal, imaging, and stool assessments before surgery and during follow-up. The primary outcome is the within-participant change in solid-meal gastric emptying half-time (T½), measured by standardized scintigraphy from baseline to 6 months. Secondary and exploratory outcomes include reflux symptoms, DeMeester score and acid exposure, route-specific gastric transit, GLP-1 and ghrelin responses, glucose metabolism, fecal elastase, gut microbiota, body-weight trajectory, comorbidities, gastroileal anastomotic caliber, and safety.",[28,67,68,29],"Gastroesophageal Reflux (GERD)","Weight Recurrence",[34,70,71,72,73,74,75,76,77],"transit bipartition","gastric emptying","scintyigraphy","T1\u002F2","DeMeester score","gastroileal anastomosis","GLP-1","fecal elastase","2026-07-30",{"date":42,"type":45},{"date":47,"type":22},{"date":82,"type":22},"2027-09-30",{"name":51,"class":52},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":53},"100599447","phase-2-metabolic-biomarkers-predicting-response-to-neoadjuvant-immunotherapy-in-non-small-cell-lung-cancer-100599447","NCT07084610","Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer","Metabolic Signatures Predictive of Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Histologically confirmed non-small cell lung cancer (NSCLC), clinical stage IB to IIIA (according to AJCC 8th edition)\n* Tumor deemed resectable by the multidisciplinary thoracic oncology team\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Adequate organ and bone marrow function\n* Ability to understand and willingness to sign a written informed consent\n\nExclusion Criteria:\n\n* Prior systemic therapy, radiotherapy, or immunotherapy for lung cancer\n* Known EGFR mutations or ALK rearrangements\n* Active autoimmune disease requiring systemic therapy within the past 2 years\n* Uncontrolled comorbidities or active infections\n* Pregnant or breastfeeding women\n* Contraindications to surgery or anesthesia\n* Known history of other malignancies within the last 3 years, except for adequately treated basal or squamous cell skin cancer, or carcinoma in situ of the cervix",{"count":92,"type":22},30,[94],"PHASE2","This study investigates metabolic glycolytic biomarkers obtained from radiological imaging (18F-FDG PET\u002FCT), immunohistochemistry (IHC), and molecular analyses, and their association with response to neoadjuvant immunotherapy in early-stage non-small cell lung cancer (NSCLC).\n\nObjective: To evaluate the relationship between glycolytic biomarkers measured by PET\u002FCT (metabolic tumor volume and SUVmax), IHC markers (GLUT-1, Ki-67, PD-L1), and molecular oncogenic alterations, with the pathological response after two cycles of neoadjuvant nivolumab (3 mg\u002Fkg) combined with platinum-based chemotherapy in patients with early-stage NSCLC \\[stage IB (tumor ≥4 cm) to IIIA\\], negative for EGFR and ALK mutations.\n\nMethods: This is a prospective, single-arm clinical study at a single institution, enrolling 30 patients. Baseline metabolic tumor volume (MTV) and SUVmax will be measured by PET\u002FCT, while IHC markers and molecular profiling will be performed on pre-treatment biopsy samples. Patients will receive neoadjuvant treatment with nivolumab (3 mg\u002Fkg, IV) combined with platinum-based chemotherapy (cisplatin 75 mg\u002Fm² or carboplatin AUC 5, plus pemetrexed 500 mg\u002Fm² for non-squamous or paclitaxel 175 mg\u002Fm² for squamous tumors) every 21 days for two cycles. All patients will undergo invasive mediastinal staging before treatment and will be treated with robotic-assisted anatomical lung resection and mediastinal lymphadenectomy after neoadjuvant therapy. Primary outcomes include major pathological response (≤10% viable tumor cells) and immune profile characterization (IHC for CD8, CD4, FOXP3, PD-1, CD68, CD163). Secondary outcomes include event-free survival and treatment toxicity.\n\nStandard of Care: Neoadjuvant chemotherapy regimens and PET\u002FCT scans are part of the institutional standard of care for NSCLC patients.\n\nConclusion: The study aims to develop a practical diagnostic approach using metabolic glycolytic biomarkers to improve selection of patients likely to benefit from neoadjuvant immunotherapy. It is expected that patients with lower glycolytic activity will have higher rates of major pathological response after two cycles of neoadjuvant nivolumab (3 mg\u002Fkg) combined with chemotherapy. These findings may support a more cost-effective immunotherapy regimen for early-stage NSCLC.",[97],"Non-Small Cell Lung Cancer","RECRUITING","2025-08-18",{"date":101,"type":45},"2025-08-22",{"date":103,"type":45},"2025-02-25",{"date":105,"type":22},"2029-01",{"name":51,"class":52},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":53},"100596390","obstructive-sleep-apnea-treatment-from-acute-to-chronic-phase-of-stroke-100596390","NCT07044830","Obstructive Sleep Apnea Treatment From Acute to Chronic Phase of Stroke","Obstructive Sleep Apnea Treatment From Acute to Chronic Phase of Stroke - A Randomized Clinical Trial","ATACS","Inclusion Criteria:\n\n* Supratentorial non-lacunar ischemic stroke, including anterior, middle, and posterior cerebral artery territories\n* Aged 18 to 80 years\n* Symptom onset or symptom recognition to admission \\\u003C 12 hours\n* NIHSS score ≥ 4 and ≤ 20 at enrollment\n* Signed informed consent form obtained from the participant or their legal representative\n\nExclusion Criteria:\n\n* Prior stroke\n* Previous diagnosis of OSA with current CPAP use or previously failed CPAP\n* Pre-stroke disability (mRS \\> 1)\n* Coma or stupor\n* Orotracheal intubation\n* Clinical instability or severe pre-existing illness (e.g., heart failure, oxygen-dependent COPD, renal or hepatic failure)\n* Psychomotor agitation\n* High likelihood of neurosurgical intervention within the first 48 hours\n* Oxygen therapy \\>2 L\u002Fmin\n* Known severe neurological disease (e.g., dementia, Parkinson's disease, multiple sclerosis, or other neurodegenerative conditions)\n* Chronic alcohol or drug use with high risk of withdrawal during hospitalization\n* Pregnant or suspected pregnant women\n* Inability to complete follow-up for any reason\n* Any contraindication to CPAP use","80 Years",{"count":117,"type":22},425,[25],"The study aims to evaluate whether early treatment of obstructive sleep apnea with continuous positive airway pressure in ischemic stroke patients has a favorable effect on functional recovery.",[121,122],"Ischemic Stroke","Obstructive Sleep Apnea",[124,122,125],"Stroke","Sleep","2025-06-21",{"date":128,"type":45},"2025-07-01",{"date":130,"type":45},"2024-02-28",{"date":132,"type":22},"2031-02-28",{"name":51,"class":52},""]